中國交建(601800.SH)擬通過未分配利潤轉增方式分別增加三家公司註冊資本
格隆匯5月13日丨中國交建(601800.SH)公佈,公司擬通過未分配利潤轉增方式分別增加附屬公司中國港灣、中國路橋和中交投資的註冊資本27.22億元、21.11億元和19.49億元;增資完成後,三家公司的註冊資本分別為60億元,60億元和125億元,仍為公司附屬公司。
公司系統分析了中國港灣、中國路橋、中交投資三家附屬公司申請增資的理由,一是盈利能力和註冊資本不相匹配,二是滿足項目運營、投標等對註冊資本的要求,三是希望通過增加註冊資本提升融資和授信額度,四是希望通過增資支持企業進一步發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.